Taiho Pharmaceutical Milestones
A Half Centry of Technical Development and Trust
[1963-1972]
| Corporate History |
R & D History |
- 1963
- Taiho Pharmaceutical Co., Ltd., established
- Capital increase to ¥100 million
- A representative of the 49 distributors nationwide assumes the position of
Board Member
- 1965
- Capital increase from ¥100 to ¥200 million
- 1969
- License with the Soviet Union to introduce Futraful in Japan
- 1971
|
- 1963
- Solcoreryl® injection (peptic ulcer and
cerebrovascular medication) introduced
- 1964
- Tiovita® Drink (nutrient tonic) introduced
- Fructone (fructose injection) introduced
- 1965
- Neophagen injection (antiallergic and liver disease medication) introduced
- 1967
- Fructlact injection (electrolyte infusion) introduced
- Neophagen tablet (antiallergic and liver disease medication) introduced
- Fructone M (intracranial and intraocular hypotension) introduced
- Pelex® Granule (cold medicine) introduced
- Glutamine Granules (peptic ulcer medication) introduced
- 1968
- Kylit injection (xylitol) introduced
- Efotinon tablet (circulatory improvement medication) introduced
- Cervical erosion treatment Solcoseryl® Vaginal Suppository introduced
- 1969
- Fladd injection (active vitamin B2) introduced
|
Top of Page
[1973-1982]
| Corporate History |
R & D History |
- 1974
- TProprietary Medicine Division established
- 1975
- Tiovita Drink introduced through an advertisement strategy
- 1976
- Business alliance formed with Nichiban Co., Ltd., with equity participation by Taiho Pharmaceutical
- 1977
- “Ot suk a Ama g i Mountain Villa ” completed
- 1978
- Business alliance formed with Kotai Kasei Co., Ltd., with equity participation by Taiho Pharmaceutical
- GMP-compliant injection drug plant completed within the Tokushima Plant; full plant integration also completed
- 1979
- New building for Quality Control Department completed
- 1980
- New research laboratory completed in Tokushima Plant
|
- 1974
- Futraful® injection and capsule (anticancer agent) introduced
- 1978
- Futraful® zupo S (anticancer suppository) introduced
- Coledes A Granule and tablet (antiinflammatory) introduced
- 1979
- Solmack® (crude drug gastrointestinal remedy) introduced
- Glutathione injection introduced
- 1980
- Futraful® E Granule (anticancer agent) introduced
- Alloask (wound healing agent) introduced
- 1981
- Futraful® E capsule and E tablet (anticancer agent) introduced
- Futraful® zupo N (anticancer agent) introduced
- Neopas F (anti-inflammatory and analgesic) introduced
- Tiovita® Hogyokusei (nutrient tonic) introduced
- 1982
- Tiovita® Gold (nutrient tonic) introduced
- Solmack® Pain (crude drug-combined gastrointestinal pain remedy) introduced
|
Top of Page
[1983-1992]
| Corporate History |
R & D History |
- 1986
- Head office moved to Chiyoda-ku, Tokyo
- State-of-the-art FA Plant completed in Tokushima
- 1987
- Synphar Laboratory established in Alberta, Canada
- 25th Anniversary Ceremony held in Tokyo and Tokushima
- 1990
- Drug Discovery Center, Training Center, and Computer Center completed in Saitama
- Taiho Pharmaceutical purchases equity and participates in management of Shinsen Iyaku Co., Ltd.
- 1991
- Okayama Plant completed
- 1st Health Forum held in Hanno City, Saitama
- 1992
- 30th Anniversary Ceremony held in Tokyo
- 21st Century Vision “Phoenix 21”
- New Corporate Song “Smile for Me” released
- Name of Shinsen Iyaku Co., Ltd. changed to Okayama Taiho Pharmaceutical Co., Ltd.
|
- 1984
- UFT® Capsule (anticancer agent) introduced
- Alloask D (wound healing agent) introduced
- Futraful® E zupo and E zupo S (anticancer agent) introduced
- 1985
- Peletack® Granule (non-aspirin analgesic and antipyretic) introduced
- 1986
- Tokuderm® (dermatological medication)
introduced
- Solmack® S (crude drug gastrointestinal remedy) introduced
- 1987
- Methaderm® cream and ointment (dermatological medication) introduced
- 1988
- UFT® Granule (anticancer agent) introduced
- 1989
- Miridacin® capsule (anti-inflammatory)
introduced
- Polycain® (antifungal medication) introduced
- Herzer® (cardiovascular medication) introduced
- 1990
- Kenicef® intravenous (antibiotic) introduced
|
Top of Page
[1993-2002]
| Corporate History |
R & D History |
- 1993
- New building enlarged for welfare completed in Okayama Plant
- 1994
- Solmack’s commercial film awarded the Dentsu Prize
- 1995
- Taiho Fine Chemical merges with Taiho Pharmaceutical
- President Yukio Kobayashi awarded the GreenDex Award from the Republic of Latvia
- 1996
- Collaborative research agreement for breast cancer therapeutics signed with SRI International (US)
- Production of Disopain anti-inflammatory tablets shifted to Yoshitomi Pharmaceutical Industries (renamed Mitsubishi Pharma Corporation,2001)
- 1997
- New investigational drug plant opens
- Clinical Research USA Office established in New York
- 1998
- Collaborative research and development agreement for angiogenesis inhibitor signed with Sugen, Inc. (U.S.A.)
- 1999
- Yukio Kobayashi, president of Taiho Pharmaceutical, becomes president of Otsuka Pharmaceutical Co., Ltd.
- 2000
- Yukio Kobayashi becomes advisor to Otsuka Pharmaceutical
- 2001
- Yukio Kobayashi becomes chairman of Taiho Pharmaceutical
- Toru Usami, previously president of Okayama Taiho Pharmaceutical, becomes president of Taiho Pharmaceutical
- 2002
- “Company History” published in commemoration of the 40th Anniversary
- Taiho Pharma U.S.A., Inc. established
|
- 1992
- UFT® E Granule (anticancer agent) introduced
- 1993
- BUP-4® tablet (for urinary incontinence and frequency) introduced
- 1994
- Miridacin® tablet (anti-inflammatory and analgesic) introduced
- 1995
- IPD® capsule (antiallergic) introduced
- Tiovita® Drink 2000 (nutrient tonic) introduced
- 1996
- Sapresta® Granule (long-lasting calcium antagonist) introduced
- 1998
- Farnezone® gel (anti-inflammatory agent) introduced
- 1999
- TS-1 capsule 20·25 (anticancer agent) introduced
- Myocalm® solution (myoclonus remedy) introduced (orphan drug)
- 2000
- New Polycain® liquid, cream and spray (antifungal) introduced
- Sales rights for Lentinan (anticancer agent) received from Ajinomoto Co., Inc.
- Protecadin® tablet (H2-receptor antagonist) introduced
- Solmack® Ichoeki (quasi-drug, crude drug-combined gastrointestinal tonic) introduced
- 2001
- TS-1 capsule for head and neck cancer additionally approved
- IPD® dry syrup 5% (antiallergic) introduced
- Harncare, the industry's first OTC product for mild incontinence, introduced
- 2002
- Tiovita® Drink 1000 (nutrient tonic) introduced
- Solmack® S Ichoeki introduced
|
Top of Page
[2003-]
| Corporate History |
R & D History |
- 2003
- Taiho Pharmaceutical signs a licensing agreement for co-promotion of morphine formulation with Dainippon Pharmaceutical Co., Ltd.
- 2004
- Taiho Pharmaceutical signs a licensing
agreement for new antiemetic Palonosetron
with Helsinn Healthcare SA (Switzerland)
- Data on UFT adjuvant therapy for lung cancer published in world's foremost
medical journal (the New England Journal of Medicine)
- Taiho Pharmaceutical signs a transfer of distributorship agreement for Zenol brand with Mikasa Pharmaceutical
- 2005
- Taiho Pharmaceutical starts collaborative research and development for injection YP-18 with Toyama Chemical Co., Ltd.
- Taiho Pharmaceutical signs a licensing agreement for anticancer agent Abraxane with American BioSciences Inc.
- 2006
- Taiho Pharmaceutical signs a licensing agreement for hay fever remedies with Meiji Dairies Corporation
- 2007
- Annex to the head office completed
- Taiho Pharmaceutical holds a ceremony for the 45th anniversary of its founding in Tokyo
- Solid medicine manufacturing plant dedicated to production of anticancer products newly established
- Data on TS-1 adjuvant therapy for gastric cancer published in medical journal (NEJM)
- 2008
- Taiho Pharmaceutical and Nippon Shinyaku sign basic agreement on the co-development and marketing of the new antipruritic agent, NS-141 in Japan
- Otsuka Holdings established
- Results of a phase III trial on combination chemotherapy of TS-1 and cisplatin for advanced gastric cancer (SPIRITS) published in UK medical journal The Lancet Oncology
- Taiho Pharmaceutical of Beijing Co.,Ltd., established
- 2009
- Taiho Pharmaceutical and aRigen Pharmaceuticals, Inc., sign codevelopment
and marketing agreement for the new ulcer treatment ARH-1029
- Results of postoperative adjuvant chemotherapy for breast cancer treatment with UFT (N-SAS-BC01) published in the US Journal of Clinical Oncology (JOC)
- Taiho Pharmaceutical and PharmaMar (Spain) enter into a license agreement on anticancer agent, Yondelis
- Taiho Pharmaceutical and GlaxoSmith-Kline strike a basic agreement on the copromotion of benign prostatic hyperplasia treatment agent, Avolve
- Taiho Pharmaceutical acquires Tsukuba Research Institute from Banyu Pharmaceutical Co., Ltd.
- Marketing approval for TS-1 obtained in China
- 2010
- Research results from the FIRIS Study published in the electronic version of The Lancet Oncology
- Marketing approval for TS-1 obtained in Taiwan
- Research results for TS-1 on non-small cell lung cancer published in the digital version of the US’s Journal of Clinical Oncology (JCO)
- 2011
- TS-1 approved in the EU as a primary treatment for advanced gastric cancer
- Taiho Pharmaceutical signs a licensing agreement on a new antiemetic combination agent with Helsinn Healthcare S.A.
- Results of the GEST clinical study on TS-1 in patients with advanced pancreatic cancer presented to the American Society of Clinical Oncology (ASCO)
- Taiho Pharmaceutical signs a distribution agreement with MSD K.K. for the anticancer compound vorinostat in Japan
- Taiho Pharmaceutical signs a co-development and commercialization agreement with Nordic Group BV for Teysuno in Europe
|
- 2003
- Uzel® tablet (reduced folic acid formulation) introduced
- Pelex® troche (cold medicine) introduced
- Solmack® EX (crude drug, gastrointestinal remedy) introduced
- TS-1 capsule additionally approved for colorectal cancer
- 2004
- Viewgel (hydro-gel wound dressing / protector) introduced
- TS-1 capsule for lung cancer additionally approved
- 2005
- Zenol xum® SX (topical analgesic/antiinflammatory) introduced
- TS-1 capsule for inoperative or recurrent breast cancer additionally approved
- 2006
- Zenol xum® FX (topical analgesic/antiinflammatory) introduced
- TS-1 capsule for pancreatic cancer additionally approved
- Harncare Jelly, a herbal medicine for mild incontinence and urinary frequency, introduced
- Solmack® Gold (quasi-drug) introduced
- 2007
- Zenol xum® introduced
- TS-1 capsule for biliary tract cancer additionally approved
- Henseki® (herbal medicine) introduced
- 2008
- Production of small-size Uzel® 25 mg tablets started in Japan
- Zosyn (injectable antibiotic) approved
- Urepearl® Plus series (for treatment of dry skin) introduced
- 2009
- Irinotecan Hydrochioride I.V. Infusion 40mg / 100mg “Taiho” approved
- Herbal gastrointestinal remedy Solmack ® Plus introduced
- Zenol Tape 35 Warm (warm sensation analgesic /anti-inflammatory, 2nd-class
OTC drug) introduced
- Solmack® EX2 (crude drug gastrointestinal remedy, 2nd-class OTC drug) introduced
- Micturition urgency, frequency, and urge incontinence in overactive bladder
approved as additional indications for BUP-4® (urinary incontinence/frequency treatment)
- 2010
- Taiho gemcitabine (I.V. infusion 200 mg and 1 gram) manufacturing and marketing approved
- Aloxi® (5-HT3 receptor antagonist antiemetic) manufacturing and marketing approved
- Reflux esophagitis approved as additional indication for Protecadin® (H2 receptor antagonist)
- Tiovita® Drink Aibitasu (3rd-class OTC drug) introduced
- Abraxane® (anticancer agent) manufacturing and marketing approved
- 2011
- 2nd-class OTC drug Zahappu® Felbinac S introduced
|
About Taiho